In June 2025, Bristol‑Myers Squibb (BMS) announced a licensing agreement for Philochem AG’s OncoACP3, a theranostic targeting Acid Phosphatase 3 in prostate cancer. The deal includes $350 million upfront and up to $1 billion in milestones, positioning BMS to enhance its radiopharmaceutical franchise and differentiate from PSMA-focused competitors.
Academia vs Immuno-oncology: A New Target
OncoACP3 offers both diagnostic (⁶⁸Ga-OncoACP3) and therapeutic (²²⁵Ac-OncoACP3) applications. Early Phase I data show precise tumour targeting with prolonged uptake—vital for both imaging and therapy. This innovation contributes to the rising global radiopharma market, projected to grow at a 10–11% CAGR and reach $26.5 billion by 2031.
A Calculated Investment with High Upside
With $350 million invested upfront, and royalties in the mid‑ to high‑single-digit range, BMS balances clinical risk with long-term potential in a prostate cancer market exceeding $5 billion. The move complements earlier acquisitions such as RayzeBio in 2022 and supports scaling actinium‑225 production for alpha‑particle therapeutics.
Strategic Outlook
-
Differentiation: ACP3’s unique tumour expression profile offers a complementary and potentially superior approach to PSMA-targeted agents.
-
Theranostics: Integrated diagnostic and therapeutic strategy facilitates personalised patient care.
-
Market positioning: By anchoring in actinium‑225 radio-therapeutics, BMS strengthens its leadership in cutting-edge oncology modalities.